Insulin Degludec
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Insulin Degludec: From Globally Approved Basal Insulin to Type 1 Diabetes Mellitus
One-Sentence Summary
Insulin degludec (Tresiba®) is an ultra-long-acting basal insulin analogue, already approved by the FDA (2015) and EMA (2013) for type 1 and type 2 diabetes, yet currently without local market registration in India. The TxGNN model predicts it may be effective for Type 1 Diabetes Mellitus — which aligns precisely with its established global therapeutic role — with 50 clinical trials and 20 publications providing exceptionally robust support for this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not locally registered; globally approved for type 1 and type 2 diabetes mellitus (FDA 2015, EMA 2013) |
| Predicted New Indication | Type 1 Diabetes Mellitus |
| TxGNN Prediction Score | 99.44% |
| Evidence Level | L1 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Insulin degludec is engineered to form soluble multi-hexamer chains upon subcutaneous injection. These multi-hexamers slowly dissociate at the injection site into dimers and monomers, which are then continuously absorbed into the bloodstream. This unique depot mechanism confers an ultra-flat, stable glucose-lowering profile with a duration of action exceeding 42 hours and virtually no pharmacodynamic peak. Day-to-day within-patient variability is approximately 20% (coefficient of variation), strikingly lower than NPH insulin at approximately 68% — a clinically decisive advantage for patients requiring predictable, round-the-clock basal insulin coverage.
In type 1 diabetes mellitus, autoimmune destruction of pancreatic β-cells eliminates endogenous insulin secretion entirely. Insulin degludec directly replaces this lost basal insulin by binding the insulin receptor and activating the IRS-1/PI3K/Akt signalling cascade. This promotes glucose uptake into skeletal muscle and adipose tissue, stimulates hepatic glycogen synthesis, and suppresses hepatic gluconeogenesis. The ultra-long, peakless action profile is particularly valuable in T1DM: any gap in basal coverage leads rapidly to hyperglycaemia and ketogenesis, and unpredictable peaks increase nocturnal hypoglycaemia risk — precisely the limitation that insulin degludec was designed to eliminate.
The TxGNN model’s high-confidence prediction (99.44%) for T1DM reflects a knowledge-graph pathway grounded in well-established pharmacology rather than speculative repurposing. Multiple Phase 3 pivotal trials in the BEGIN programme, alongside more recent head-to-head comparator trials (ONWARDS 6, QWINT-5, EXPECT), have confirmed equivalent or superior HbA1c reduction with a clinically meaningful reduction in nocturnal hypoglycaemia compared to insulin glargine and insulin detemir. The local “not marketed” status most plausibly reflects an absence of a local regulatory filing rather than any deficiency in clinical evidence.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01513473 | Phase 3 | Completed | 350 | BEGIN Young 1: IDeg vs insulin detemir in children and adolescents aged 1 to <18 years with T1DM on a basal-bolus regimen with insulin aspart; 26-week efficacy and safety comparison with 26-week extension, conducted across Africa, Asia, Europe and USA |
| NCT00982228 | Phase 3 | Completed | 629 | BEGIN BB T1 LONG: 52-week multinational treat-to-target trial comparing IDeg + insulin aspart versus insulin glargine + insulin aspart in T1DM adults, with an extension period (BEGIN T1) |
| NCT02670915 | Phase 3 | Completed | 834 | Faster-acting insulin aspart (Fiasp) vs NovoRapid, both in combination with IDeg as background basal insulin, in children and adolescents with T1DM; global multi-centre trial |
| NCT02030600 | Phase 3 | Completed | 721 | SWITCH 2: Double-blind, two-period cross-over trial comparing IDeg vs insulin glargine with or without OADs in T2DM; largest sample size in this dataset, with high internal validity |
| NCT02392117 | N/A | Completed | 1,262 | Large-scale prospective non-interventional observational study of Tresiba® safety and effectiveness in real-world T1DM and T2DM populations across Europe; supplements RCT external validity |
| NCT04196231 | Phase 4 | Completed | 258 | BEYOND: Open-label 3-arm RCT evaluating the durability of IDeg/GLP-1RA and IDeg/SGLT-2i combination regimens versus basal-bolus therapy in poorly controlled T2DM; real-world usage context |
| NCT03938740 | Phase 2 | Completed | 61 | Exploratory randomised open-label 2-arm trial comparing hepatic-directed vesicle–insulin lispro versus IDeg to determine optimum basal insulin dosing algorithms in T1DM |
| NCT01773798 | Phase 1 | Completed | 33 | PK/PD properties of insulin degludec/insulin aspart 15 (IDegAsp) in T1DM subjects; supports dose-response characterisation and formulation understanding |
| NCT01076634 | Phase 1 | Completed | 33 | Comparison of two IDeg formulations on pharmacodynamic properties in T1DM subjects; conducted in Europe |
| NCT01704417 | Phase 1 | Completed | 40 | Head-to-head comparison of the effect of exercise on blood glucose between IDeg and insulin glargine in T1DM subjects; conducted in Europe |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39270686 | 2024 | RCT (Phase 3) | Lancet | QWINT-5: Once-weekly insulin efsitora alfa vs once-daily IDeg in T1DM adults; Phase 3 non-inferiority trial — IDeg served as the gold-standard active comparator, affirming its benchmark status in T1DM |
| 37863084 | 2023 | RCT | Lancet | ONWARDS 6: Once-weekly insulin icodec vs once-daily IDeg in T1DM adults; Phase 3a head-to-head efficacy and safety trial |
| 36623517 | 2023 | RCT (Phase 3) | Lancet Diabetes & Endocrinology | EXPECT trial: IDeg vs insulin detemir, both in combination with insulin aspart, in pregnant women with T1DM; multinational open-label non-inferiority trial |
| 36763996 | 2022 | Systematic review / Meta-analysis | Clinical Therapeutics | IDeg vs insulin glargine and insulin detemir in T1DM and T2DM: comparable HbA1c reduction with a consistent, clinically relevant reduction in hypoglycaemic episodes |
| 34643020 | 2022 | RCT | Diabetes, Obesity & Metabolism | HypoDeg trial: Randomised controlled cross-over trial comparing IDeg vs insulin glargine U100 in T1DM patients prone to nocturnal severe hypoglycaemia |
| 36800034 | 2023 | RCT | European Journal of Pediatrics | Three-arm RCT comparing IDeg vs insulin glargine vs NPH insulin in toddlers and preschoolers (ages 2–6 yr) with T1DM; glycaemic variability and time-in-range outcomes |
| 31055056 | 2020 | Systematic review | Diabetes & Metabolism | Comprehensive synthesis of randomised and observational trials of IDeg in T1DM and T2DM; highlights better fasting glucose control and consistently lower nocturnal hypoglycaemia vs comparators |
| 37290466 | 2023 | Review | Lancet Diabetes & Endocrinology | Management of T1DM in pregnancy: lifestyle, pharmacological treatment including IDeg, and novel technologies (CGM, insulin pumps) for achieving glycaemic targets |
| 23890782 | 2014 | Review | Endocrinologia y Nutricion | Early clinical overview of IDeg’s ultra-long-acting mechanism (multi-hexamer depot formation) and Phase 2/3 data in T1DM and T2DM |
| 25143741 | 2014 | Review | Vascular Health and Risk Management | Insulin degludec/insulin aspart combination for T1DM and T2DM: pharmacological rationale and pivotal clinical trial evidence |
India Market Information
Insulin degludec (Tresiba®) currently has no registered authorizations in the India market. No marketing approval records or license registrations were identified through the regulatory data query.
For reference, insulin degludec is approved under the following major regulatory jurisdictions:
| Jurisdiction | Approval Year | Approved Indication |
|---|---|---|
| EMA (Europe) | 2013 | Type 1 and type 2 diabetes mellitus in adults |
| FDA (USA) | 2015 | Type 1 and type 2 diabetes mellitus in adults and paediatric patients (≥1 year) |
| Global (multiple markets) | 2013–present | Available as Tresiba® (100 U/mL and 200 U/mL) and Ryzodeg® (IDeg/IAsp combination) |
The absence of India registration reflects a regulatory filing gap rather than a safety or efficacy concern.
Safety Considerations
Drug Interactions (351 total interactions identified; key examples listed below):
| Interacting Drug | Interaction Level | Clinical Note |
|---|---|---|
| Epinephrine | Moderate | Catecholamines antagonise insulin’s glucose-lowering effect; monitor blood glucose closely |
| Hydrocortisone | Moderate | Systemic corticosteroids elevate blood glucose and reduce insulin efficacy; dose adjustment may be required |
| Acebutolol | Moderate | Beta-blockers can mask hypoglycaemia symptoms (except sweating); use with caution |
| Hydrochlorothiazide | Moderate | Thiazide diuretics may impair glucose tolerance; insulin dose titration may be needed |
| Metformin | Moderate | Additive glucose-lowering effect; combined use is common and generally beneficial but requires monitoring |
| Pioglitazone | Moderate | Additive glucose-lowering; increased risk of fluid retention and heart failure; caution in at-risk patients |
| Alogliptin | Moderate | Additive glucose-lowering with DPP-4 inhibitor; heightened hypoglycaemia risk |
| Ethanol | Moderate | Alcohol inhibits hepatic gluconeogenesis and can substantially potentiate hypoglycaemia |
| Formoterol / Salbutamol | Moderate | Beta-2 agonists elevate blood glucose and may counteract insulin action |
| Estradiol / Levonorgestrel / Norethisterone | Moderate | Hormonal preparations may alter insulin requirements; regular blood glucose monitoring advised |
Please refer to the package insert for the full list of 351 interactions, complete warnings, contraindications, and special population guidance (pregnancy, renal/hepatic impairment, elderly).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Insulin degludec carries one of the strongest evidence bases of any basal insulin in modern diabetes therapeutics — with multiple completed Phase 3 multinational RCTs (BEGIN programme), post-marketing surveillance studies across tens of thousands of patients, and active benchmark-comparator status in Phase 3 trials of next-generation once-weekly basal insulins (ONWARDS 6, QWINT-5). The L1 evidence classification is unambiguous. The India “not marketed” status represents a regulatory filing gap that does not reflect any therapeutic uncertainty.
To proceed, the following is needed:
- Submit a local CDSCO marketing authorisation application, citing FDA and EMA approval dossiers as primary supporting documentation
- Obtain and thoroughly review the full prescribing information / SmPC to document India-specific safety labelling, warnings, and contraindications (currently a data gap flagged as blocking)
- Establish cold-chain logistics and storage infrastructure adequate for insulin products (2–8°C; do not freeze)
- Confirm paediatric dosing guidance and registration scope (T1DM in patients ≥1 year as per FDA label)
- Set up post-marketing pharmacovigilance and adverse event reporting mechanisms compliant with CDSCO requirements
- Develop healthcare provider education materials highlighting the clinical advantages of IDeg over currently available basal insulin options (lower nocturnal hypoglycaemia, flexible once-daily dosing window, lower day-to-day variability)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.